September - 20216September - 2 - 2021, volume 05 - Issue 10 (ISSN 2691-4093)Published by ValleyMedia, Inc. Managing EditorAlex D'souzaEditorial StaffVisualizerJohn GothamSalesAndrew D'Souzaandrew.dsouza@medicaltechoutlook.com510.996.5123Contact usEmailPhone:510 230 0396 Fax:510-894-8405sales@medicaltechoutlook.comeditor@medicaltechoutlook.commarketing@medicaltechoutlook.comJoshua Parker Merlin WatsonJoe Philip Laura PintoTo subscribe to MedicalTech OutlookVisit www.medicaltechoutlook.com Copyright © 2021 ValleyMedia Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.*Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffAlex D'souzaManaging Editoreditor@medicaltechoutlook.comIn vitro diagnostics (IVD) are already in wide use in the healthcare business to aid in diagnosis and decision-making. Though the IVD market has been significantly thinned due to regulatory and compliance issues, it remains one of the most competitive segments in the broader biomedical materials market. The pressing necessity of IVD is even more pertinent nowadays, owing to COVID testing. Previously solely available in the clinical context, technological advancement has made it possible for many point-of-care (POC)-based IVD tests to be performed at home, with almost instantaneous and accurate results. More advanced diagnostics that conduct and analyze tests using only a single drop of blood, urine, or saliva have also been invented, paving the path for innovation in clinical testing. On the road to further innovation, factors like global health trends, lab management practices, sample testing methods, and diagnostic technology will be determining future trends in IVD. For now, cutting-edge diagnostic technologies like non-invasive prenatal testing and next generation sequencing comprising of Illumina, Roche 454, SOLiD, and Ion Torrent: Proton sequencing technologies will be leading the way to transform clinical testing in never seen before ways. Liquid biopsy, currently going through regulatory processes, is also set to be another frontrunner in the IVD space.With such exciting developments, the IVD market is predicted to grow by leaps and bounds, keeping pace with rapidly evolving technology and clinical testing methodologies. Given the shifting regulatory landscape, growing customer expectations, and industry consolidation, such growth must include stringent quality assurance procedures at every step of manufacturing testing equipment and reagents.It's obvious that healthcare organizations and clinical laboratories require the best in vitro diagnostic solutions in order to deliver top-quality diagnostic technology and services to their patients and customers. We hope this edition shows you the path to find the appropriate in vitro diagnostic solution provider suited to your needs.Let us know your thoughts!At the Cusp of Transforming Clinical TestingSarah FernandesEDITORIAL
< Page 5 | Page 7 >